Talphera, Inc.

1.2300-0.07 (-5.38%)

Oct 29, 4:00:00 PM EDT · NasdaqCM · TLPH · USD

Upcoming Earnings

Report date

Nov 12, 2025 (in 13 days)

Key Stats

Market Cap

59.43M

P/E (TTM)

Basic EPS (TTM)

-0.39

Dividend Yield

Recent Filings

8-K

10/22/25Oct 22, 2025

8-K

Talphera appoints CorMedix CEO to board

10/16/25Oct 16, 2025

Talphera appointed Joseph Todisco, CEO of CorMedix, to its board as a Class III director on October 14, 2025, fulfilling CorMedix's nomination right from a September 2025 securities purchase agreement. Todisco joins the compensation committee with an initial grant of 6,397 restricted stock units and options for 38,381 shares at $1.11, vesting over three years. This bolsters governance ties amid CorMedix's 60-day exclusive negotiation right for a full acquisition post-positive NEPHRO CRRT study results, potentially shaping Talphera's strategic path.

8-K

Talphera raises $17M in private placement

9/10/25Sep 10, 2025

Talphera closed a $17 million private placement on September 10, 2025, issuing 25 million shares at $0.55 each and pre-funded warrants for 5.8 million more shares, with CorMedix as a key investor gaining board designation rights while owning at least 25% of its stake. Investors committed to another $12 million tranche upon positive NEPHRO CRRT study results and a $0.6875 VWAP threshold. CorMedix secures a 60-day exclusive negotiation for a full acquisition post-study success, followed by a nine-month match right on better third-party offers. This bolsters Talphera's runway for clinical milestones, yet ties strategic moves to trial outcomes.

10-Q

Q2 FY2025 results

8/14/25Aug 14, 2025

Talphera narrowed its Q2 net loss to $3.5M from $3.8M a year earlier, while YTD through June 30, 2025, the shortfall eased to $6.1M from $7.8M, thanks to R&D expenses dropping 21% to $1.5M on lower headcount and SG&A trimming 7% to $2.2M amid board pay cuts. Operating losses improved q/q and y/y (derived), with no revenue yet but $27K YTD from discontinued ops offsetting some burn. Cash dipped to $6.8M from $8.9M year-end, fueled by $4.3M from an April equity raise, yet the firm flags going-concern doubts without fresh funding. No non-GAAP metrics disclosed in the 10-Q. Litigation drags on, with appeals pending in securities suits that could spike costs.

8-K

Talphera Q2 loss narrows

8/14/25Aug 14, 2025

Talphera reported Q2 2025 net loss of $3.5 million, down from $3.8 million last year, with cash at $6.8 million. Enrollment hit 15 patients in the NEPHRO study, fueled by new sites that snagged 90% of recruits; completion eyes year-end. Momentum builds. Expenses drop to $16-17 million guidance, but funding hinges on milestones.

About

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is based in San Mateo, California.

CEO

Mr. Vincent J. Angotti

IPO

2/11/2011

Website

https://talphera.com

Employees

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic